CBAY CymaBay Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CBAY

Price (delayed)

$19.13

Market cap

$2.17B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.93

Enterprise value

$2B

CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need. CymaBay is developing seladelpar, a potent, selective, ...

Highlights
The quick ratio has soared by 87% since the previous quarter and by 85% year-on-year
CymaBay Therapeutics's EPS has increased by 26% YoY but it has decreased by 4.5% from the previous quarter
CymaBay Therapeutics's net income has increased by 15% YoY but it has decreased by 12% from the previous quarter
CymaBay Therapeutics's debt has increased by 21% YoY and by 4.9% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.cymabay.com
Peers: PFE XNCR BMY PTCT

Key stats

What are the main financial stats of CBAY
Market
Shares outstanding
113.4M
Market cap
$2.17B
Enterprise value
$2B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
5.76
Price to sales (P/S)
65.2
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
64.48
Earnings
Revenue
$31.02M
EBIT
-$72.16M
EBITDA
-$71.35M
Free cash flow
-$64.19M
Per share
EPS
-$0.93
Free cash flow per share
-$0.61
Book value per share
$3.32
Revenue per share
$0.29
TBVPS
$4.27
Balance sheet
Total assets
$451.05M
Total liabilities
$124.86M
Debt
$104.09M
Equity
$326.19M
Working capital
$427.99M
Liquidity
Debt to equity
0.32
Current ratio
22.76
Quick ratio
22.31
Net debt/EBITDA
2.38
Margins
EBITDA margin
-230%
Gross margin
100%
Net margin
-290.5%
Operating margin
-266.5%
Efficiency
Return on assets
-33.8%
Return on equity
-62.7%
Return on invested capital
-29.9%
Return on capital employed
-16.7%
Return on sales
-232.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CBAY stock price

How has the CymaBay Therapeutics stock price performed over time
Intraday
1.86%
1 week
6.87%
1 month
16.65%
1 year
465.98%
YTD
205.1%
QTD
28.3%

Financial performance

How have CymaBay Therapeutics's revenue and profit performed over time
Revenue
$31.02M
Gross profit
$31.02M
Operating income
-$82.66M
Net income
-$90.1M
Gross margin
100%
Net margin
-290.5%
CymaBay Therapeutics's net income has increased by 15% YoY but it has decreased by 12% from the previous quarter
CBAY's operating margin is down by 15% since the previous quarter
CymaBay Therapeutics's operating income has decreased by 15% from the previous quarter but it has increased by 12% YoY
CymaBay Therapeutics's net margin has decreased by 12% from the previous quarter

Growth

What is CymaBay Therapeutics's growth rate over time

Valuation

What is CymaBay Therapeutics stock price valuation
P/E
N/A
P/B
5.76
P/S
65.2
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
64.48
CymaBay Therapeutics's EPS has increased by 26% YoY but it has decreased by 4.5% from the previous quarter
The P/B is 52% higher than the 5-year quarterly average of 3.8 but 38% lower than the last 4 quarters average of 9.3

Efficiency

How efficient is CymaBay Therapeutics business performance
CBAY's ROIC is up by 44% YoY but it is down by 6% QoQ
CBAY's ROE is up by 43% YoY and by 40% QoQ
CBAY's ROA is up by 41% YoY and by 19% QoQ
CymaBay Therapeutics's ROS has decreased by 13% from the previous quarter

Dividends

What is CBAY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CBAY.

Financial health

How did CymaBay Therapeutics financials performed over time
CBAY's total assets has soared by 183% YoY and by 99% from the previous quarter
The quick ratio has soared by 87% since the previous quarter and by 85% year-on-year
CymaBay Therapeutics's debt is 68% less than its equity
CBAY's debt to equity has plunged by 78% YoY and by 65% from the previous quarter
CymaBay Therapeutics's debt has increased by 21% YoY and by 4.9% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.